Subscribe
Be the first with the news that moves the market- Novo Nordisk (NYSE:NVO) stock jumped to a record high after its Wegovy treatment cut the risk of heart issues by 20 per cent
- In a late-stage select trial, data showed that its obesity drug reduced the risk of major cardiovascular events such as heart attacks or strokes
- The company intends to file for regulatory approvals of a label indication expansion for Wegovy in the United States and European Union later this year
- Novo Nordisk opened trading at US$161.36 per share
Novo Nordisk (NYSE:NVO) stock jumped to a record high after its Wegovy treatment cut the risk of heart issues by 20 per cent.
In a late-stage select trial, data showed that its obesity drug reduced the risk of major cardiovascular events such as heart attacks or strokes.
The trial enrolled more than 17,000 adults aged 45 years and older with overweight or obesity and established cardiovascular disease with no prior history of diabetes.
In a news release, the company said the trial achieved its primary objective by demonstrating a “statistically significant and superior reduction” in major adverse cardiovascular events for people treated with Wegovy (semaglutide) 2.4 mg compared to a placebo.
Wegovy injection 2.4 mg is described by the company as a once-weekly glucagon-like peptide-1(GLP-1) receptor agonist indicated for chronic weight management in adults and adolescents aged more than 12 years with obesity (BMI greater than 30 for adults, BMI more than 95th percentile for age and sex for adolescents), or some adults with excess weight (BMI above 27) (overweight) who also have weight-related medical problems.
The company intends to file for regulatory approvals of a label indication expansion for Wegovy in the United States and European Union later this year.
Novo Nordisk is a global healthcare company engaged in diabetes care. The company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates through two business segments: diabetes and obesity care and biopharmaceuticals.
Novo Nordisk opened trading at US$161.36 per share and its shares are 54.2 per cent higher than this time last year.
Join the discussion: Find out what everybody’s saying about this stock on the Novo Nordisk Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
